Full analysis of anifrolumab price and purchase methods

Anilumab (anifrolumab-fnia) injection is an innovative biologic therapy designed for patients with moderate to severesystemic lupus erythematosus (SLE) who are concurrently receiving other lupus treatments. As a monoclonal antibody, anilumab has demonstrated significant clinical value in the field of lupus treatment due to its unique mechanism of action.

Systemic lupus erythematosus is a complex autoimmune disease in which the patient's immune system mistakenly attacks its own tissues, causing damage to multiple organs throughout the body. Anilumab effectively blocks the signaling pathway of type I interferon by precisely targeting the type I interferon receptor (IFNAR1). Type I interferon plays a key role in the pathogenesis of lupus, and its overexpression can exacerbate abnormal activation of the immune system and inflammatory response. By inhibiting this pathway, anilumab can regulate the immune system's excessive response, thereby helping to control lupus symptoms and reduce patients' suffering.

Anilumab is administered by intravenous infusion. This treatment method allows the drug to be rapidly distributed throughout the body and exert its therapeutic effect. During the treatment process, anilumab not only helps relieve patients' clinical symptoms, such as joint pain, skin damage, and fatigue, but also reduces the patient's dependence on traditional immunosuppressants such as glucocorticoids to a certain extent, thereby reducing the possible side effects of long-term use of these drugs.

However, anilumab is not suitable for allSLE patients. Its use must strictly follow the doctor's instructions and carry out individualized assessment according to the patient's specific situation. At the same time, patients need to pay close attention to possible side effects during treatment, such as infections, allergic reactions, etc., and communicate with their doctors in a timely manner. Overall, anilumab provides a new treatment option for patients with moderate to severe systemic lupus erythematosus, which is expected to bring hope and improve the quality of life to more patients.

Currently, anilumab is not available in China, and patients cannot obtain the drug directly from domestic hospitals. Some data show that the specification of anilumab available in Europe is 300 mg, and the price is about 17,000 yuan. If the patient needs anilumab, it is recommended to consult with Yaode’s overseas medical consultant.

Reference link: https://www.mayoclinic.org/drugs-supplements/anifrolumab-fnia-intravenous-route/description/drg-20520346